Skye Bioscience, Inc. received a notification on May 13, 2026, from Nasdaq stating that its stockholders' equity of $9,011,804 does not meet the $10,000,000 requirement for continued listing. The company has until June 29, 2026, to submit a plan to regain compliance or potentially appeal the decision.